1. Ciummo, Stefania Livia, Sorrentino, Carlo, Fieni, Cristiano, Di Carlo, Emma. 2023. Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways. In Journal of experimental & clinical cancer research : CR, 42, 336. doi:10.1186/s13046-023-02902-y. https://pubmed.ncbi.nlm.nih.gov/38087324/
2. Ding, Yu, Cao, Qifeng, Wang, Chen, Duan, Huangqi, Shen, Haibo. . LGALS4 as a Prognostic Factor in Urothelial Carcinoma of Bladder Affects Cell Functions. In Technology in cancer research & treatment, 18, 1533033819876601. doi:10.1177/1533033819876601. https://pubmed.ncbi.nlm.nih.gov/31558111/
3. Cheraghi-Shavi, Tayebeh, Jalal, Razieh, Minuchehr, Zarrin. 2023. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach. In PloS one, 18, e0289535. doi:10.1371/journal.pone.0289535. https://pubmed.ncbi.nlm.nih.gov/37535601/
4. Acharjee, Animesh, Agarwal, Prasoon, Nash, Katrina, Rahman, Taufiq, Gkoutos, Georgios V. 2021. Immune infiltration and prognostic and diagnostic use of LGALS4 in colon adenocarcinoma and bladder urothelial carcinoma. In American journal of translational research, 13, 11353-11363. doi:. https://pubmed.ncbi.nlm.nih.gov/34786063/
5. Li, Shengjie, Yang, Kaifeng, Ye, Jiayou, Sun, Bin, Xu, Jun. 2025. LGALS4 inhibits glycolysis and promotes apoptosis of colorectal cancer cells via β‑catenin signaling. In Oncology letters, 29, 126. doi:10.3892/ol.2025.14873. https://pubmed.ncbi.nlm.nih.gov/39807100/
智鼠故事 
